Open AccessThis article is
- freely available
Biosimilars: Company Strategies to Capture Value from the Biologics Market
Escuela Técnica Superior de Ingeniería, Universidad de Santiago de Compostela, Rúa Lope Gómez de Marzoa s/n, Campus Vida 15782, Santiago de Compostela, Spain
Institute of Biotechnology, University of Cambridge, Tennis Court Rd, CB41QT, Cambridge, UK
* Authors to whom correspondence should be addressed.
Received: 8 November 2012; in revised form: 5 December 2012 / Accepted: 6 December 2012 / Published: 12 December 2012
Abstract: Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
Keywords: biosimilar; patent cliff; biopharmaceutical industry; market strategy; biologics
Citations to this Article
Cite This Article
MDPI and ACS Style
Calo-Fernández, B.; Martínez-Hurtado, J.L. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 2012, 5, 1393-1408.
Calo-Fernández B, Martínez-Hurtado JL. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals. 2012; 5(12):1393-1408.
Calo-Fernández, Bruno; Martínez-Hurtado, Juan L. 2012. "Biosimilars: Company Strategies to Capture Value from the Biologics Market." Pharmaceuticals 5, no. 12: 1393-1408.